JP2024502821A - 処置方法 - Google Patents

処置方法 Download PDF

Info

Publication number
JP2024502821A
JP2024502821A JP2023540497A JP2023540497A JP2024502821A JP 2024502821 A JP2024502821 A JP 2024502821A JP 2023540497 A JP2023540497 A JP 2023540497A JP 2023540497 A JP2023540497 A JP 2023540497A JP 2024502821 A JP2024502821 A JP 2024502821A
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
solvate
acceptable salt
hydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023540497A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024502821A5 (https=
Inventor
ウォルシュ，ブランドン・ジェームス
アダムス，ジョン・ダブリュー
アンソポロス，プロドロモス
スタウバー，ケーテ・リン
Original Assignee
アリーナ ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アリーナ ファーマシューティカルズ， インコーポレイテッド filed Critical アリーナ ファーマシューティカルズ， インコーポレイテッド
Publication of JP2024502821A publication Critical patent/JP2024502821A/ja
Publication of JP2024502821A5 publication Critical patent/JP2024502821A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023540497A 2020-12-31 2021-12-30 処置方法 Pending JP2024502821A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063133160P 2020-12-31 2020-12-31
US63/133,160 2020-12-31
PCT/US2021/065777 WO2022147318A1 (en) 2020-12-31 2021-12-30 Methods of treatment

Publications (2)

Publication Number Publication Date
JP2024502821A true JP2024502821A (ja) 2024-01-23
JP2024502821A5 JP2024502821A5 (https=) 2024-12-24

Family

ID=82260959

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023540497A Pending JP2024502821A (ja) 2020-12-31 2021-12-30 処置方法

Country Status (7)

Country Link
US (1) US20240058350A1 (https=)
EP (1) EP4271375A4 (https=)
JP (1) JP2024502821A (https=)
AR (1) AR124542A1 (https=)
CA (1) CA3206840A1 (https=)
TW (1) TW202241446A (https=)
WO (1) WO2022147318A1 (https=)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008520695A (ja) * 2004-11-19 2008-06-19 アリーナ ファーマシューティカルズ， インコーポレイテッド ５−ｈｔ２ａセロトニン受容体媒介障害の処置に有用な５−ｈｔ２ａセロトニン受容体のモジュレーターとしての３−フェニル−ピラゾール誘導体の使用
WO2015109220A1 (en) * 2014-01-17 2015-07-23 President And Fellows Of Harvard College Platelet decoy and use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2646076C (en) * 2006-05-18 2015-06-30 Arena Pharmaceuticals, Inc. Ethers, secondary amines and derivatives thereof as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
US8084475B2 (en) * 2009-12-04 2011-12-27 Intermune, Inc. Pirfenidone therapy and inducers of cytochrome P450
WO2011075596A1 (en) * 2009-12-18 2011-06-23 Arena Pharmaceuticals, Inc. Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
ES2702848T3 (es) * 2011-02-23 2019-03-05 Coeruleus Ltd Complejos de flumazenil, composiciones que los comprenden y usos de los mismos
AU2012327224A1 (en) * 2011-11-18 2013-06-06 Apotex Technologies Inc. Methods of treatment with deferiprone
TR201905773T4 (tr) * 2013-10-01 2019-05-21 Sphingotec Gmbh Bir majör advers kardiyak olayla karşılaşma riskinin tahmin edilmesi için bir usul.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008520695A (ja) * 2004-11-19 2008-06-19 アリーナ ファーマシューティカルズ， インコーポレイテッド ５−ｈｔ２ａセロトニン受容体媒介障害の処置に有用な５−ｈｔ２ａセロトニン受容体のモジュレーターとしての３−フェニル−ピラゾール誘導体の使用
WO2015109220A1 (en) * 2014-01-17 2015-07-23 President And Fellows Of Harvard College Platelet decoy and use thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
J. MED. CHEM., vol. 53, JPN7025005337, 2010, pages 4412 - 4421, ISSN: 0005750920 *
J. PHAMACOL. EXP. THERAP., vol. 331, JPN7025005339, 2009, pages 96 - 103, ISSN: 0005750922 *
循環制御, vol. 37, JPN7025005338, 2016, pages 30 - 35, ISSN: 0005750921 *

Also Published As

Publication number Publication date
US20240058350A1 (en) 2024-02-22
AR124542A1 (es) 2023-04-05
EP4271375A1 (en) 2023-11-08
TW202241446A (zh) 2022-11-01
CA3206840A1 (en) 2022-07-07
EP4271375A4 (en) 2024-11-20
WO2022147318A1 (en) 2022-07-07

Similar Documents

Publication Publication Date Title
Tripathi et al. Haemodynamic effects of acute and chronic administration of low‐dose carvedilol, a vasodilating β‐blocker, in patients with cirrhosis and portal hypertension
Banon et al. The usefulness of ranolazine for the treatment of refractory chronic stable angina pectoris as determined from a systematic review of randomized controlled trials
AU2022404695B2 (en) New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases
US20250099466A1 (en) Milvexian for prevention and treatment of thromboembolic disorders
US8680052B1 (en) Methods of treating, reducing the incidence of, and/or preventing ischemic events
US20200046673A1 (en) Method of treating patients with a factor Xa inhibitor, Aspirin, and Verapamil
AU2022407131C1 (en) New oral pharmaceutical composition and dose regimen for the therapy of progressive fibrosing interstitial lung diseases
US20220241294A1 (en) Bisfluoroalkyl-1,4-benzodiazepinone compounds for treating notch-activated breast cancer
WO2019074536A1 (en) METHODS OF TREATING PROSTATE CANCER BY ADMINISTERING ABIRATERONE ACETATE AND PREDNISONE WITH ANDROGENIC SEPARATION THERAPY
JP6840197B2 (ja) 虚血性事象を処置し、その発生率を低減させ、かつ／または予防する方法
JP2024502821A (ja) 処置方法
Chapple et al. Tamsulosin oral controlled absorption system (OCAS) in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH): efficacy and tolerability in a phase 2b dose-response study
TW202216129A (zh) 排尿症狀治療劑
HK40073112A (en) Methods of treating, reducing the incidence of, and/or preventing ischemic events
JP2024520819A (ja) Ｍｍｐ－１２阻害薬の安全な投与
JP2024503377A (ja) バダデュスタットを使用した治療方法
JP2024502821A5 (https=)
EA046794B1 (ru) Применение производного глутаримида для терапии заболеваний, ассоциированных с аберрантной активностью интерлейкина-6

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241216

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241216

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251210

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260226